Galcanezumab: all 32 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingNCT07655440Phase 4
• Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's DiseaseRecruitingNCT07323927Early Phase 1
• Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedNCT05284019Phase 4Results posted
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineCompletedNCT05127486Phase 4Results posted
• Galcanezumab for Vestibular MigraineCompletedNCT04417361Phase 2Results posted
• A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP AntagonistCompletedNCT04294147Phase 4Results posted
• Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of ActionCompletedNCT04271202Phase 4Results posted
• Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineCompletedNCT04179474Phase 1Results posted
• Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/FibromyalgiaCompletedNCT04158752Phase 4Results posted
• A Study of Galcanezumab (LY2951742) in Healthy Chinese ParticipantsCompletedNCT04085289Phase 1Results posted
• A Study of Galcanezumab (LY2951742) in Participants With Episodic MigraineCompletedNCT03963232Phase 3Results posted
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant MigraineCompletedNCT03559257Phase 3Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With MigraineCompletedNCT02959190Phase 3Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigraineCompletedNCT02959177Phase 2Results posted
• A Study of Galcanezumab in Healthy Participants.CompletedNCT02836613Phase 1Results posted
• A Study of LY2951742 (Galcanezumab) in Participants With Cluster HeadacheCompletedNCT02797951Phase 3Results posted
• A Safety Study of Galcanezumab in Participants With Migraine, With or Without AuraCompletedNCT02614287Phase 3Results posted
• Evaluation of Galcanezumab in the Prevention of Chronic MigraineCompletedNCT02614261Phase 3Results posted
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyCompletedNCT02614196Phase 3Results posted
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 StudyCompletedNCT02614183Phase 3Results posted
• A Study of Galcanezumab in Healthy ParticipantsCompletedNCT02576951Phase 1Results posted
• A Study of Galcanezumab in Participants With Chronic Cluster HeadacheCompletedNCT02438826Phase 3Results posted
• A Study Of Galcanezumab In Participants With Episodic Cluster HeadacheCompletedNCT02397473Phase 3Results posted
• A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee PainTerminatedNCT02192190Phase 2Results posted
• A Study of Galcanezumab (LY2951742) in Participants With Migraine HeadacheCompletedNCT02163993Phase 2Results posted
• A Study of LY2951742 in Healthy Japanese and Caucasian ParticipantsCompletedNCT02104765Phase 1Results posted
• A Study of LY2951742 in Participants With MigraineCompletedNCT01625988Phase 2Results posted
• A Study of LY2951742 in Healthy VolunteersCompletedNCT01337596Phase 1Results posted
• The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous HeadachesCompletedNCT06901518Phase 4
• Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research StudyTerminatedNCT05492695Phase 4
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineActive, not recruitingNCT04616326Phase 3
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineActive, not recruitingNCT03432286Phase 3

← Galcanezumab overview